FMP
NASDAQ
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
10.43 USD
-1.26 (-12.08%)
Valuation Date:
May 1, 2024 4:00 PM
Share Price on Valuation Date
$10.43
Stock Beta
1.494
Shares Outstanding
31673000